Development of molecular targeting drugs that can regulate IL-10 functions
Project/Area Number |
22501022
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Tumor immunology
|
Research Institution | Chiba University |
Principal Investigator |
TAMURA Yutaka 千葉大学, 大学院・医学研究院, 准教授 (50263174)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 分子標的薬 / 悪性黒色腫 / IL-10 / 免疫療法 / コンピュータ・シミュレーション / 計算科学 |
Research Abstract |
The malignant melanoma has highest malignancy in skin cancer. We aimed at the development of the new cure of the malignant melanoma. We constructed molecular target medicine with the next property: the noninvasive identification method to let deliver and accumulate molecular target medicine (IL-10 decoy which targeted IL-10) selectively and perform a malignant melanoma, the hyperthermia treatment with the release of IL-10 decoy containing it.
|
Report
(4 results)
Research Products
(19 results)